A recent assessment comparing the benefits of two separate value frameworks produced by the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) found the frameworks offer similar benefits involving new cancer therapies, according to a report by the American Journal of Managed Care.
Per the report, the assessment analyzed clinical benefits of more than 100 cancer drugs, and found similar results in about two-thirds of them.
The frameworks were reportedly developed to deliver clear, unbiased and reliable assessments of potential clinical benefits from new cancer therapies.
ASCO’s framework was published in 2015 and revised in 2016, while ESMO’s framework was published in 2015 and revised in 2017.
To read the full report on AJMC, click here.